Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore (Nasdaq: ECOR) will announce its financial results for Q4 and the fiscal year ending December 31, 2020, after market close on March 11, 2021. A conference call is scheduled for 4:30 PM ET for management to discuss the results. The company focuses on bioelectronic medicine, particularly through non-invasive vagus nerve stimulation therapy, addressing conditions such as cluster headaches and migraines in adults and adolescents.
electroCore, Inc. (Nasdaq: ECOR) announced participation in two investor conferences. The first is the H.C. Wainwright Global Life Sciences Conference, featuring a pre-recorded fireside chat available from March 9, 2021, at 7:00 a.m. ET. The second is the M Vest LLC and Maxim Group LLC Emerging Growth Virtual Conference, starting with a presentation on March 17, 2021, at 9:00 a.m. ET. Both events will include virtual investor meetings and replays will be accessible on the company's website for 90 days.
electroCore, Inc. (Nasdaq: ECOR) has entered a three-year agreement with Medistar, making them the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator in Australia. This follows the Australian Therapeutic Goods Administration's approval for the sale of gammaCore products. The partnership aims to provide patients suffering from primary headache disorders with access to this innovative therapy. Medistar will officially launch gammaCore at the ANZHS Headache Annual Scientific Meeting on March 13-14, 2021.
electroCore, Inc. (Nasdaq: ECOR) has announced the completion of patient enrollment for its SAVIOR-1 study, which evaluates the impact of non-invasive vagus nerve stimulation (nVNS) on respiratory symptoms in COVID-19 patients. This significant step aims to uncover potential therapeutic benefits for respiratory distress caused by the virus. Dr. Carlos Tornero highlights the promise of vagus nerve stimulation in treating respiratory functions. The study is backed by electroCore and underscores the ongoing search for effective COVID-19 treatments.
electroCore (Nasdaq: ECOR) announced that gammaCore will remain listed in the NHS Supply Chain catalogue for an additional two years, extending its availability through June 3, 2023. This listing allows NHS trusts to continuously procure gammaCore Sapphire™ (nVNS), facilitating better access for patients in the UK needing non-invasive vagus nerve stimulation for migraine and cluster headache treatments. The inclusion is pivotal for ensuring that this innovative therapy is accessible and cost-effective for healthcare organizations amid budgetary constraints.
electroCore (Nasdaq: ECOR) announced FDA clearance on February 12, 2021, for its gammaCore device, now allowing its use in treating migraines in adolescents aged 12 to 17. This label expansion covers acute and preventive treatment for various headache types. With an estimated 10% of school-age children experiencing migraines, this development positions gammaCore as a unique non-pharmaceutical treatment option. The clearance supports prior trials showing significant effectiveness in migraine management without acute medication reliance.
On February 11, 2021, electroCore, Inc. (Nasdaq: ECOR) announced the completion of patient enrollment in its SAVIOR-1 study, which evaluates non-invasive vagus nerve stimulation (nVNS) for COVID-19 patients experiencing respiratory symptoms. Conducted in Valencia, Spain, the trial enrolled 110 patients aged 18 and older, randomized to receive either nVNS with standard care or standard care alone. The study aims to assess clinical events, safety, and proinflammatory cytokine levels, with preliminary results expected soon and full results in a peer-reviewed publication later this year.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a peer-reviewed paper in Colorectal Disease, detailing a study on non-invasive vagus nerve stimulation (nVNS) for treating ileus after colorectal surgery. Conducted at St. James’s University Hospital with 40 subjects, the trial aimed to assess safety and feasibility. Results indicated nVNS was safe and improved several recovery metrics, such as reduced morphine use by 25.6% post-surgery. Future studies, including the TRANSIT study with 140 patients, aim to explore nVNS's potential further.
electroCore (Nasdaq: ECOR), a bioelectronic medicine company, will participate in a fireside chat at the BTIG Virtual MedTech Conference from February 17-19, 2021. The chat is scheduled for February 17 at 12:30 PM ET. A live webcast will be available on the company's website. The company focuses on non-invasive vagus nerve stimulation therapy to treat conditions such as cluster headaches and migraines.
electroCore (Nasdaq: ECOR) announced that gammaCore Sapphire (nVNS) is included in NHS England's new MedTech Funding Mandate Policy 2021/22, effective April 1, 2021. This policy supports NHS commissioners and providers in adopting NICE-approved technologies to enhance patient outcomes. It emphasizes that gammaCore could save the NHS up to £4,561,223 over five years. The policy aims for effective, affordable, and cost-saving innovations, transitioning from shorter renewal cycles to more stable reimbursement structures.
